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Propylthiouracil (PTU) has been held responsible for diffuse alveolar hemorrhage (DAH)
with positive antineutrophil cytoplasmic antibody (ANCA) and capillaritis. We describe a
case of a 23-year-old pregnant female with Grave’s disease treated with PTU who
presented with flu-like symptoms and progressive dyspnea. Open lung biopsy showed DAH
without evidence of capillaritis. All serologies were negative. Five days after PTU
withdrawal and intravenous steroid therapy, the patient improved dramatically. She
remained symptom free without relapse 9 months after the episode. To the best of our
knowledge, this is the first reported case of PTU-related alveolar hemorrhage with
negative serologic markers and without capillaritis.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Propylthiouracil (PTU) has been held responsible for diffuse
alveolar hemorrhage (DAH) in patients treated for Graves’
disease.1–9 To the best of our knowledge, all PTU-related
DAH cases reported to date had been associated with serum
antineutrophil cytoplasmic antibody (ANCA) positivity and
small vessel vasculitis with or without glomerulonephritis.
Here, we describe a case of ANCA negative PTU-induced DAH
without demonstrable capillaritis.Elsevier Ltd. All rights reserved.
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A 23-year-old African American woman in the 34th week of
pregnancy presented with 2 days of dyspnea and dry cough.
She denied hemoptysis, subjective fever, chills, hematuria
or lower extremity edema. She had been compliant with
prenatal care. The patient had been diagnosed with Grave’s
disease 5 years prior and had been treated with PTU
intermittently. Her physician had restarted treatment with
PTU 100mg three times daily several weeks prior to
presentation.
On admission, the temperature was 38.9 1C, the respira-
tory rate was 20 breaths/min, the heart rate 110 beats/min
and the BP was 110/80. Oxygen saturation was 97% on room
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N.P. Hadjiangelis, T.J. Harkin866air. The physical examination was significant for a goiter, a
II/VI holosystolic murmur audible at the axilla and a
protuberant abdomen. The WBC count was 8400-cells/mL;
hemoglobin 10.2 g/dL; platelets 186,000/mL. The BUN was
3mg/dL and serum creatinine was 0.2mg/dL. The electro-
lytes, liver function tests and coagulation studies were
normal. The admission arterial blood gas measurement on
room air was: pH 7.48, PaCO2 32mmHg, PaO2 86mmHg,
HCO3 23mEq/L, SaO2 97%, with a calculated alveolar–arter-
ial oxygen difference of 24mmHg. Other pertinent studies
included: low thyroid stimulating hormone (o 0.004mIU/L),
elevated free T4 (2.38 ng/dL), and mildly elevated erythro-
cyte sedimentation rate (24mm/h). Urinalysis revealed rare
red blood cells/high power field and 1+protein without
casts. Chest CT scan with intravenous contrast was negative
for pulmonary embolus but showed small multifocal ground-
glass opacities in the periphery of the lung parenchyma,
predominately in the upper lobes but also in the right lower
lobe. Cardiomegaly and thyromegaly were also noted.
The echocardiogram demonstrated moderate mitral insuffi-
ciency, mild aortic and tricuspid insufficiency with left
ventricular ejection fraction approximately 45–50%. The
measured systolic pulmonary artery pressure was 30mmHg.
On the second day of hospitalization, the patient became
more dyspneic. Repeat arterial blood gas measurement on
room air of pH 7.43, PaCO2 34mmHg, PaO2 58mmHg, HCO3
23mEq/L, SaO2 94%, alveolar–arterial oxygen difference of
50mmHg. A repeat chest CTscan revealed progression of the
bilateral multifocal opacities. Pulmonary function testing
(PFT) was not performed due to severe dyspnea. PTU was
stopped and methylprednisolone 60mg was administered
intravenously every 6 h.
On the third day of hospitalization, the patient underwent
cesarean section delivering a healthy baby boy. The delivery
was immediately followed by flexible bronchoscopy with
bronchoalveolar lavage, which was grossly bloody, and an
open lung biopsy via a mini-thoracotomy.
The biopsy showed hemorrhage into the alveolar spaces
without inflammation or destruction of the alveolar septa
(see Fig. 1). Immunofluorescent microscopy showed noFigure 1 Hematoxylin–eosin stain of the lung shows hemor-
rhage into the alveolar spaces without inflammation or
destruction of the alveolar septa.evidence of immunoglobulin deposition. Serum studies for
cytoplasmic antineutrophil cytoplasmic antibody (c-ANCA),
perinuclear ANCA (p-ANCA), anti-glomerular basement
membrane antibodies (anti-GBM), rheumatoid factor (RF),
antinuclear antibody (ANA), HIV and hepatitis serologies
were all negative. The findings were consistent with bland
alveolar hemorrhage.
By the fifth day of hospitalization, the patient showed
marked improvement. She was normoxemic on room air.
Chest radiograph showed diminution of the patchy alveolar
pattern densities. The patient was discharged home on oral
steroids tapered over 1 month. Methimazole replaced PTU
for thyroid suppression therapy. One month after discharge
home she reported no symptoms.
Nine months latter, the patient remains in remission and
enjoys a healthy life with her baby boy. The repeat chest
X-ray showed complete resolution of the infiltrates. The
serologic markers (c-ANCA, p-ANCA, RF, ANA) remained
negative.Discussion
Propylthiouracil (PTU) is an antithyroid drug widely used for
the treatment of Graves’ disease. Adverse reactions to PTU
reportedly occur in less than 1% of the patients receiving the
drug.10 We found nine previous case reports in the literature
of DAH ascribed to treatment with PTU.1–9
In 1999 Dhillon et al. described the first known case of
PTU-induced DAH with documented pulmonary capillaritis
on open lung biopsy and crescentic glomerulonephritis.3 The
patient was 23 years old in the first trimester of pregnancy
on PTU therapy for Grave’s disease. She developed PTU-
induced p-ANCA positive vasculitic syndrome resulting in
DAH and crescentic glomerulonephritis. Her symptoms
resolved completely after PTU was withdrawn and steroid
therapy was instituted. Repeat p-ANCA 11 months later was
negative while a test for anti-myeloperoxidase (anti-MPO)
was positive.
To the best of our knowledge all cases of PTU-related DAH
with or without glomerulonephritis reported to date were p-
ANCA and/or c-ANCA positive. All patients had Graves’
disease on PTU therapy for a minimum of 2 weeks to a
maximum of 9 years. The majority of them were female and
their age ranged from 4 to 72 years. All patients presented
with a flu-like prodrome (fever, arthralgia, myalgia, fatigue,
malaise) and some with hemoptysis, hematuria and rash.
Their ESR ranged from 30 to 78 and all were p-ANCA positive
except two patients; one had c-ANCA positive serology1 and
the other had anti-myeloperoxidase (anti-MPO) positive
serology.6 The PTU was discontinued in all cases. All of
them received steroids except one, whose symptoms
disappeared 4 weeks after PTU withdrawal without steroid
use.2 Two patients were treated with steroids and cyclopho-
sphamide4,7 and a third received plasma exchange therapy
in addition to steroids and cyclophosphamide.5 All nine
reported cases responded to treatment with complete
resolution of the symptoms in 2 weeks minimum to 5 months
maximum of therapy.
Our patient developed DAH with negative serologies
without evidence of capillaritis on open lung biopsy and
without demonstrable glomerulonephritis. She was in the
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several weeks before admission. While it is difficult to prove
a causal relationship between PTU and alveolar hemorrhage,
the diagnosis of PTU-related DAH is supported by the
following observations:(1) The disease developed during PTU administration.
(2) The symptoms and signs resolved 5 days after PTU
discontinuation (albeit in the setting of systemic
corticosteroid administration), enough time for elimina-
tion of the drug. PTU half-life (T1/2) is about 1–2 h with
normal renal function. The drug and its metabolites are
excreted in urine, with about 35% of the dose excreted
within 24 h.10(3) There was no relapse during 9 months of follow up.The pathophysiologic mechanisms in PTU-related alveolar
hemorrhage are still obscure. The syndrome of diffuse
alveolar hemorrhage (DAH) may present with three different
histologic patterns: (a) pulmonary capillaritis; (b) bland
alveolar hemorrhage; and (c) diffuse alveolar damage. DAH
with underlying isolated pauciimmune pulmonary capillaritis
has been described in eight patients, three males and five
females, without any PTU use.11 None of the eight had
clinical or serologic findings of an associated underlying
systemic disorder.
Our case is somewhat dissimilar to those previously
reported. PTU-related DAH may have taken place in this
patient due to a different mechanism. The inherent changes
of the immune system during pregnancy in addition to some
undefined effect of PTU may be involved in the pathogenesis
of DAH in this case. Alternatively, the interrupted nature
of PTU therapy for this patient may have contributed in
some way.
In conclusion, we report the first case of PTU-related DAH
in a pregnant woman with negative serologies and without
capillaritis. We believe that PTU may cause DAH by a
mechanism other than capillaritis. Clinicians should recog-
nize a potential risk of rapid deterioration in pulmonary andor renal function during PTU therapy. Early identification of
the inciting agent is essential for recovery or prevention of
recurrence.
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